V. Craig Jordan - Top Cited Publications

Top Cited Publications

  • Cummings, S. R.; Eckert, S.; Krueger, K. A.; Grady, D.; Powles, T. J.; Cauley, J. A.; Norton, L.; Nickelsen, T. et al. (1999). "The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation". JAMA: the Journal of the American Medical Association 281 (23): 2189–2197. doi:10.1001/jama.281.23.2189. PMID 10376571. edit (1,140 citations as of July 3, 2012).
  • Furr, B. J.; Jordan, V. C. (1984). "The pharmacology and clinical uses of tamoxifen". Pharmacology & therapeutics 25 (2): 127–205. doi:10.1016/0163-7258(84)90043-3. PMID 6438654. edit (751 citations as of July 3, 2012).
  • Love, R. R.; Mazess, R. B.; Barden, H. S.; Epstein, S.; Newcomb, P. A.; Jordan, V. C.; Carbone, P. P.; Demets, D. L. (1992). "Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer". New England Journal of Medicine 326 (13): 852–856. doi:10.1056/NEJM199203263261302. PMID 1542321. edit (723 citations as of July 3, 2012).
  • Vogel, V.G., Costantino, J.P., Wickerham, D.L., Cronin, W.M., Cecchini, R.S., Atkins, J.N., Bevers, T.B., Fehrenbacher, L., Pajon (jr), E.R., Wade, J.L. III, Robidoux, A., Margolese, R.G., James, J., Lippman, S.M., Runowicz, C.D., Ganz, P.A., Reis, S.E., McCaskill-Stevens, W., Ford, L.G., Jordan, V.C. and Wolmark, N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Journal of the American Medical Association 295:2727-41, 2006. (588 citations as of July 3, 2012).
  • MacGregor, J. I.; Jordan, V. C. (1998). "Basic guide to the mechanisms of antiestrogen action". Pharmacological reviews 50 (2): 151–196. PMID 9647865. edit (467 citations as of July 3, 2012).
  • Jordan, V. C. (1984). "Biochemical pharmacology of antiestrogen action". Pharmacological reviews 36 (4): 245–276. PMID 6395141. edit (425 citations as of July 3, 2012).
  • Jordan, V.C., Collins, M.M., Rowsby L. and Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. Journal of Endocrinology 75:305-316, 1977. (400 citations as of July 3, 2012).
  • Jordan, V.C. and Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocrine Reviews 11:578-610, 1990. (382 citations as of July 3, 2012).
  • Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., Stepan, J. J., Powles, T. J., Morrow, M., Costa, A., Silfen, S. L., Walls, E. L., Schmitt, H., Muchmore, D. B. and Jordan, V. C. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Research and Treatment 65: 125-134, 2001. (349 citations as of July 3, 2012).
  • Lerner, L.J. and Jordan, V.C. Development of antiestrogens and their use in breast cancer (Eighth Cain Memorial award lecture). Cancer Research 50:4177-4189, 1990. (341 citations as of July 3, 2012).
  • Gottardis, M.M., Robinson, S. P., Satyaswaroop, P.G. and Jordan, V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research 48:812-815, 1988. (339 citations as of July 3, 2012).
  • Gottardis, M.M. and Jordan, V.C. Development of tamoxifen-stimulated growth of MCF 7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48:5183-5187, 1988. (332 citations as of July 3, 2012).
  • Jordan, V.C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. European Journal of Cancer 12:419-424, 1976. (304 citations as of July 3, 2012).
  • Love, R.R., Wiebe, D. A., Newcomb, P.A., Cameron, L., Leventhal, H., Jordan, V.C., Feyzi, J. and DeMets, D. L. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Annals of Internal Medicine 115:860-864, 1991. (298 citations as of July 3, 2012).
  • Gottardis, M. M. and Jordan, V.C. The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N nitrosomethylurea-induced rat mammary carcinoma model. Cancer Research 47:4020-4024, 1987. (261 citations as of July 3, 2012).
  • Love, R.R., Newcomb, P.A., Wiebe, D. A., Surawicz, T.S., Jordan, V.C., Carbone, P.P. and DeMets, D.L. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. Journal of National Cancer Institute 82:1327 1331, 1990. (250 citations as of July 3, 2012).
  • Jordan, V.C., Phelps, E. and Lindgren J.U. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Research and Treatment 10:31-35, 1987. (230 citations as of July 3, 2012).
  • Jiang, S.Y. and Jordan, V.C. Growth regulation of estrogen receptor negative breast cancer cells transfected with cDNA's for estrogen receptor. Journal of the National Cancer Institute 84:580-591, 1992. (218 citations as of July 3, 2012).
  • Jordan, V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Part I: Receptor interactions. Journal of Medicinal Chemistry 46:883-908, 2003.(210 citations as of July 3, 2012).
  • Jordan, V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Part II: Clinical considerations and new agents. Journal of Medicinal Chemistry 46:1081-1111, 2003.(200 citations as of July 3, 2012).
  • Gottardis, M.M., Jiang, S.Y., Jeng, M.H. and Jordan, V.C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Research 49:4090-4093, 1989. (198 citations as of July 3, 2012).
  • Pink, J.J. and Jordan, V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Research 56:2321-2330, 1996. (192 citations as of July 3, 2012).
  • Trump, D.L., Smith, D.C., Ellis, P.G., Rogers, M.P., Schold, S.C., Winer, E.P., Ponella, T.J., Jordan, V.C. and Fine, R.L. High dose oral tamoxifen, a potential multidrug resistance reversal agent: Phase I trial in combination with vinblastine. Journal of the National Cancer Institute 84:1811-1816, 1992. (189 citations as of July 3, 2012).
  • Jordan, V.C. A current view of tamoxifen for the treatment and prevention of breast cancer (Gaddum Memorial Lecture). British Journal of Pharmacology 110:507-517, 1993. (187 citations as of July 3, 2012).
  • Jordan, V.C. and Morrow, M.M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocrine Reviews 20:253-278, 1999. (176 citations as of July 3, 2012).
  • Jordan, V.C. Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery 2:205-213, 2003. (173 citations as of July 3, 2012).
  • Jordan, V.C. and Allen, K.E. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. European Journal of Cancer 16:239-251, 1980. (170 citations as of July 3, 2012).
  • Jensen, E.V. and Jordan, V.C. The estrogen receptor: a model for molecular medicine. Clinical Cancer Research 9:1980-1989, 2003. (161 citations as of July 3, 2012).
  • Robinson, S.P., Langan-Fahey, S.M., Johnson, D.A. and Jordan, V.C. Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metabolism and Disposition 19:36-43, 1991. (152 citations as of July 3, 2012).
  • Jordan, V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5:207-213, 2004. (146 citations as of July 3, 2012).

Read more about this topic:  V. Craig Jordan

Famous quotes containing the words top, cited and/or publications:

    “The necessary has never been man’s top priority. The passionate pursuit of the nonessential and the extravagant is one of the chief traits of human uniqueness. Unlike other forms of life, man’s greatest exertions are made in the pursuit not of necessities but of superfluities.”
    —Eric Hoffer (1902–1983)

    “Private property is held sacred in all good governments, and particularly in our own. Yet shall the fear of invading it prevent a general from marching his army over a cornfield or burning a house which protects the enemy? A thousand other instances might be cited to show that laws must sometimes be silent when necessity speaks.”
    —Andrew Jackson (1767–1845)

    “Dr. Calder [a Unitarian minister] said of Dr. [Samuel] Johnson on the publications of Boswell and Mrs. Piozzi, that he was like Actaeon, torn to pieces by his own pack.”
    —Horace Walpole (1717–1797)